Healthy Living Washington: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Washington.

Press releases published on November 18, 2026

Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
Shoppers Drug Mart announces the sale of QHR Technologies to LGI Healthcare Solutions along with continued collaboration in Canadian healthcare
Quantum-Si Achieves Historic Milestone in Protein Sequencing with Single-Molecule Detection of All 20 Amino Acids on Proteus™
Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
CMS Finalizes Reassignment of Gastric Alimetry® Test to Higher Payment Level, Increasing Medicare Hospital Outpatient Payment by Approximately 144%
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
Surgery Partners, Inc. Announces Increased Consent Fee in Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032
SELLAS Life Sciences meldet positive Ergebnisse der zulassungsrelevanten Phase III-Studie REGAL zu immuntherapeutischem Krebsimpfstoff Galinpepimut-S (GPS), die eine statistisch signifikante und klinisch bedeutsame Verbesserung in Bezug auf…
SELLAS Life Sciences annonce une les résultats positifs de l’étude pivot de phase III REGAL : l’utilisation du vaccin immunothérapeutique contre le cancer, le Galinpepimut-S (GPS), a démontré une amélioration statistiquement significative et…
חברת SELLAS Life Sciences מודיעה על נתונים חיוביים מניסוי ה-REGAL – מחקר מכריע בשלב 3 – המראים כי החיסון האימונותרפי לסרטן, Galinpepimut-S (GPS), הוביל לשיפור מובהק סטטיסטית ומשמעותי מבחינה קלינית בהישרדות הכוללת בקרב חולים עם לוקמיה מיאלואידית חריפה (…
SELLAS Life Sciences Mengumumkan Data Positif dari Uji Klinis Penting Fase 3 REGAL yang Menunjukkan bahwa Vaksin Imunoterapi Kanker Galinpepimut-S (GPS) Memberikan Peningkatan Kesintasan Keseluruhan yang Signifikan Secara Statistik dan Bermakna Secara…
セラス・ライフ・サイエンシズ、リーガルと呼ばれる重要な第3相試験の良好なデータを発表、がん免疫療法ワクチンであるガリンペピムト-S (GPS)…
SELLAS 라이프사이언스, 면역항암 백신 갈린페피무트-S(GPS)의 급성 골수성 백혈병 환자 대상 전체생존기간 개선 효과 입증한 핵심 임상 3상 REGAL 시험에서 긍정적 결과 발표
SELLAS Life Sciences Mengumumkan Data Positif Kajian Pivotal Fasa 3 REGAL yang Menunjukkan bahawa Vaksin Kanser Imunoterapeutik Galinpepimut-S (GPS) Meningkatkan Kelangsungan Hidup Keseluruhan secara Signifikan dari Segi Statistik dan Bermakna dari…
SELLAS Life Sciences ประกาศข้อมูลเชิงบวกที่เป็นจุดเปลี่ยนสำคัญจากการศึกษาวิจัยทางคลินิก REGAL ระยะที่ 3 ซึ่งแสดงให้เห็นว่าวัคซีนภูมิคุ้มกันบำบัดรักษามะเร็ง Galinpepimut-S (GPS) ช่วยให้อัตราการรอดชีวิตโดยรวมในผู้ป่วยโรคมะเร็งเม็ดเลือดขาวชนิดมัยออยด์เฉีย…
SELLAS Life Sciences 公布关键性 3 期 REGAL 试验积极数据:免疫治疗癌症疫苗 Galinpepimut-S (GPS) 在急性髓系白血病患者中展现出具有统计学显著性和临床意义的总生存期改善

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthy Living Washington

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.